User:Wonderful2017/sandbox

iCarbonX,founded in October 2015, aims to build an ecosystem of digital life based on a combination of an individual’s biological, behavioral and psychological data, the Internet and artificial intelligence.

The management team has deep experience in omics technology, mobile health, medical service, biological data analysis, artificial intelligence and data mining, etc. Based on a growing digital life network, together with the world's leading partners, we plan to interpret and study your digital life to provide personalized products and services for a healthier and better life.

History
October 27th, 2015:iCarbonX(Shenzhen)Company Limited was formally established.

January 22th, 2016: iCarbonX international Limited was formally established in HongKong.

April 11th, 2016: iCarbonX finished its Pre-A Round financing led by Tencent with 1 billion yuan investment. The assessed value of iCarbonX reaches 1 billion U.S. dollars.

August 19th, 2016: iCarbonX completed an investment of 30 million yuan to SHENZHEN PRAJNASYS CORP.,LTD, in order to extend its network to big data insurance.

September 10th, 2016: iCarbonX announced its acquisition of Imagu Vision Technologies and the establishment of iCarbonX-Israel R&D center.

January 5th, 2017, iCarbonX announced that seven companies have joined iCarbonX’s Digital Life Alliance and the iCarbonX ecosystem has invested a total of nearly $400 million in the seven companies that form the alliance: SomaLogic, HealthTell, PatientsLikeMe, AOBiome, GALT, Imagu and Robustnique.

January 5th, 2017, Meum™ has been officially released to the public, which is the digital health management platform built up by iCarbonX and its digital life ecosystem partners.

Jun Wang
Dr. Jun Wang, Founder and CEO of iCarbonX. Dr. Wang earned a bachelor’s degree in artificial intelligence and a Ph.D. in bioinformatics from Peking University. In 1999, Dr. Wang co-founded BGI, which is now widely recognized as one of world’s premier research facilities committed to excellence in genome sciences. During this time, Dr. Wang managed three rounds of fundraising (about 1B$ in total), and acquired a U.S. public company, Complete Genomics. He was recognized with numerous awards and nominations, such as His Royal Highness Prince Foundation, and “Fortune’s 40 under 40” by Fortune Magazine (2013) and Highly Cited Researchers 2015” by Thomson Reuters.